Emerging Treatment Approaches and Multidisciplinary Management of Unresectable Stage III Non-Small Cell Lung Cancer - Episode 12

Closing Thoughts and Clinical Pearls: Future Perspectives in NSCLC

The expert discussion concludes with reflections on the rapid advancements in the treatment of locally advanced lung cancer, emphasizing the importance of personalized therapy, multidisciplinary collaboration, and continued progress in improving patient outcomes.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Defining Resectability in Stage III NSCLC: Addressing Key Controversies
    EP. 2: Multidisciplinary Strategies for Optimizing Care in Unresectable Stage III NSCLC
    EP. 3: Optimizing Biomarker Testing for Unresectable Stage III NSCLC
    EP. 4: Overcoming Barriers to Biomarker Testing in Unresectable NSCLC: Strategies for Improved Access and Implementation
    EP. 5: Tailoring Chemoradiotherapy Approaches in Unresectable Stage III NSCLC
    EP. 6: Consolidation Durvalumab in Unresectable Stage III NSCLC: Management Strategies and the Role of ctDNA
    EP. 7: Assessment and Management Strategies for Pneumonitis in Durvalumab Consolidation Post Chemoradiotherapy
    EP. 8: Exploring the Role of SBRT in Unresectable NSCLC: Patient Selection and Trial Insights
    EP. 9: A 76-Year-Old Woman With Locally Advanced Unresectable Stage III EGFRm NSCLC
    EP. 10: Expert Insights on the LAURA Trial: Osimertinib After CRT in Unresectable Stage III EGFRm NSCLC as a New Standard of Care
    EP. 11: Key Takeaways From the PACIFIC-2 Trial: The Role of Concurrent Immunotherapy With CRT
    Now Viewing
    EP. 12: Closing Thoughts and Clinical Pearls: Future Perspectives in NSCLC

    Video content above is prompted by the following:

    • Please provide closing thoughts and any clinical pearls that may be of value.
    • Please provide closing thoughts and any clinical pearls that may be of value.
    x